What is in Shire’s Vyvanse “Clinical Pharmacology and Biopharmaceutics Review”?
Shire’s clinical pharmacology and biopharmaceutics review for Vyvanse is a regulatory document prepared for the U.S. FDA during the drug’s approval process. It focuses on how Vyvanse behaves in the body (pharmacokinetics) and how the drug’s formulation and performance relate to exposure (biopharmaceutics). Those reviews typically cover study design and results such as absorption after dosing, conversion to the active ingredient, exposure over time, dose proportionality, and assessment of factors that may affect exposure (like fed/fasted state and other patient-relevant conditions).
How does Vyvanse work from a pharmacology standpoint (why the biopharm review matters)?
Vyvanse is an extended-release prodrug formulation. In the body, it is designed to convert to the active amphetamine form, so the clinical pharmacology review pays close attention to:
- the time course of exposure (how quickly active drug appears and how long it persists),
- the relationship between the administered dose and systemic exposure,
- and whether the extended-release design produces the intended, smoother exposure profile.
Because the active effect depends on conversion and absorption, biopharmaceutics details (formulation, release characteristics, and exposure metrics) are central to linking dosing to clinical performance.
What pharmacokinetic topics are usually addressed in these FDA pharmacology/biopharm reviews?
While the exact subsection wording is document-specific, these reviews commonly analyze:
- single- and multiple-dose pharmacokinetics (peak/trough behavior and accumulation),
- food effects (fed vs fasted absorption and exposure),
- distribution and metabolism patterns relevant to amphetamine exposure,
- renal impairment or other intrinsic/extrinsic factors that may change exposure,
- and exposure–response considerations when supported by the dataset.
Where can you find the Shire Vyvanse clinical pharmacology/biopharm review?
These FDA review documents are often accessible through the FDA’s drug-approval archive (for example, in the “Drugs@FDA” entry for Vyvanse) or through the FDA’s document-lending systems where available for the original review package. If you share the exact Vyvanse NDA/BLA number or the year/approval cycle you mean, I can help narrow down which posted review matches that document set.
Is DrugPatentWatch.com useful for this specific request?
DrugPatentWatch.com is more geared toward patents, exclusivity, and regulatory history than it is toward the detailed clinical pharmacology/biopharm report text. It can still help confirm the regulatory timeline and related exclusivity/patent context around Vyvanse, which may be useful when locating the correct FDA document package. If you want, tell me whether you’re looking for the document itself or for the patent/exclusivity context around it, and I’ll tailor the search accordingly.
Source: DrugPatentWatch.com
---
Sources
- https://www.drugpatentwatch.com/